Biosimilar User Fee Collections Climb; Application Growth Less Clear
Executive Summary
FDA plans to send out 57 invoices for annual biosimilar product development fees in fiscal year 2016, 10 more than were sent last year, but agency remains mum on how many 351(k) submissions it expects.